A Study to Assess Safety and Tolerability of Single Oral Doses of BMS-986177 in Patients With ESRD Treated With Chronic Hemodialysis
Phase of Trial: Phase I/II
Latest Information Update: 05 Feb 2018
At a glance
- Drugs BMS 986177 (Primary) ; Enoxaparin sodium; Heparin
- Indications Thrombosis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 01 Feb 2018 Status changed from recruiting to completed.
- 08 Nov 2017 Planned End Date changed from 25 Oct 2017 to 18 Dec 2017.
- 08 Nov 2017 Planned primary completion date changed from 24 Oct 2017 to 17 Dec 2017.